enzh-TWfrdeitjaptrues

The Dana-Farber Bing Center for Waldenstrom's Macroglobulinemia Web site is intended to provide general information about the program, its care and research programs, and about Waldenstrom's Macroglobulinemia and related diseases. This site also provides links to health information that may be written by Dana-Farber staff or by outside providers, and access (links) to some external Web sites for your convenience. The Dana-Farber Waldenstrom's Macroglobulinemia Program is not responsible for the availability, accuracy, or content of these external sites, nor does it endorse them.

No Medical Advice Given
This site is not an attempt to practice medicine or provide specific medical advice, nor does the use of the site establish a doctor-patient relationship. For medical treatment or answers to personal questions, we strongly encourage you to consult with a qualified health care provider. For advice about your own care, please ask your doctor!

Restrictions on Use
You assume full responsibility for using the information on this site, and you understand and agree that the Dana-Farber Waldenstrom's Macroglobulinemia Program is not responsible or liable for any claim, loss, or damage resulting from its use. While we try to keep the information on the site as accurate as possible, we disclaim any warranty concerning its accuracy, timeliness, and completeness, and any other warranty, express or implied, including warranties of merchantability or fitness for a particular purpose. The Dana-Farber Waldenstrom's Macroglobulinemia Program also does not warrant that access to the site will be error- or virus-free.

Copyright Infringement
Material on the Dana-Farber Waldenstrom's Macroglobulinemia Program Web site is protected by copyright law. Unless otherwise stated, users may print or download information from this site for personal, non-commercial use only. Permission to reprint or otherwise reproduce any document in whole or in part is prohibited, unless prior written consent is obtained from the copyright owner.

Latest Bing Center News

Dr Castillo on the Efficacy of Iopofosine I 131 in Waldenström Macroglobulinemia

Dr Castillo on the Efficacy of Iopofosine I 131 in Waldenström Macroglobulinemia

Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, institute physician, Dana-Farber Cancer Institute, associate professor, medicine, Harvard Medical School, discusses the efficacy of treatment with iopofosine I 131 (previously CLR 131) in patients with Waldenström macroglobulinemia.

Read more..

Waldenstrom Macroglobulinemia: Who Gets What and When?

Waldenstrom Macroglobulinemia: Who Gets What and When?

As many as 50% of people at the time of their Waldenstrom macroglobulinemia (WM) diagnosis won’t need drug therapy for a number of years. We spoke with Shayna Sarosiek, MD, hematologist/oncologist from at the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute in Boston, to share what “supportive treatments” could help in the meantime.

Read more..

In Memoriam of Dr. Enrica Morra

In Memoriam of Dr. Enrica Morra

Dear Members of the Waldenstrom’s Macroglobulinemia Community: I wanted to share with you the sad news that our colleague and friend, Dr. Enrica Morra recently passed away. Dr. Morra was the Co-Chair of 6th International Workshop on Waldenstrom’s Macroglobulinemia (IWWM) which was held in Venice, Italy (2010), and a recipient of the Jan Gosta Waldenstrom Award for Lifetime Contributions to Waldenstrom’s Macroglobulinemia at the 8th IWWM in London, UK (2014).

Read more..

ASH-2023 Posters Presented

ASH-2023 Posters Presented

The following posters were presented by the Bing Center at the ASH 2023 meeting, December 9-12, 2023 in San Diego. For more information about the ASH 2023 meeting, please visit https://www.hematology.org/meetings/annual-meeting.

Read more..

ASH 2023 - Bing Center Abstracts to be Presented

ASH 2023 - Bing Center Abstracts to be Presented

The following abstracts represent the research that will be presented by the Bing Center at the ASH 2023 meeting, December 9-12, 2023 in San Diego. For more information about the ASH 2023 meeting, please visit https://www.hematology.org/meetings/annual-meeting.

Read more..

Waldenstrom: Reaching the Relapsed Refractory Stage

Waldenstrom: Reaching the Relapsed Refractory Stage

Waldenstrom Macroglobulinemia (WM) is not curable, which means most patients will either reach the relapsed or refractory stage at some point in their journey. Patient Power spoke with Shayna Sarosiek, MD, hematologist/oncologist from at the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute in Boston, to share what reaching these stages mean for WM patients.

Read more..

Waldenstrom Macroglobulinemia: Who Gets What and When?

Waldenstrom Macroglobulinemia: Who Gets What and When?

As many as 50% of people at the time of their Waldenstrom macroglobulinemia (WM) diagnosis won’t need drug therapy for a number of years. We spoke with Shayna Sarosiek, MD, hematologist/oncologist from at the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute in Boston, to share what “supportive treatments” could help in the meantime.

Read more..

We want YOU to join our Jimmy FundRaiser community!

We want YOU to join our Jimmy FundRaiser community!

We want YOU to join our Jimmy FundRaiser community! The Dana-Farber Community Fundraising Event (CFE) program is where community members hold their own fundraisers or events on behalf of Dana-Farber and the Jimmy Fund. Fundraisers range from bake sales to hiking mountains, walking a 5k, and holding a virtual cooking class. Holding a fundraiser can be an outlet for individuals or families who want to take an “action” towards supporting a loved one, remembering a loved one, or fighting their own fight against cancer.

Read more..

Zachary Hunter - 20 Years at Dana-Farber!

Zachary Hunter - 20 Years at Dana-Farber!

I first met Zach in 2004 when I joined the Bing Center as a volunteer. He was managing clinical trials, and immediately became my "go-to" person when I needed help or advice on any technical issue. Zach created the first WM Workshop website, and then taught me how to maintain it. I was able to build on that knowledge to create other websites.

Read more..

What insights can multi-omics provide into the mechanism of disease progression in WM?

What insights can multi-omics provide into the mechanism of disease progression in WM?

On behalf of the International Waldenstrom's Macroglobulinemia Foundation (IWMF), the Lymphoma Hub was pleased to speak with Zachary Hunter, Dana-Farber Cancer Institute, Boston, US. We asked, What insights can multi-omics provide into the mechanism of disease progression in Waldenstrom’s macroglobulinemia (WM)?

Read more..